No single company can achieve comprehensive coverage, specialization, and regulatory excellence all at once. As a group, we can. VITAIRA is the platform where partner companies actively shape their future together.
Quality is non-negotiable
When it comes to pharmaceuticals, the quality of logistics determines their efficacy and safety. That is why we implement uniform, validated standards across the group—GDP-compliant and GMP-certified—and continuously raise the bar.
Entrepreneurship Endures
We acquire companies to alleviate operational burdens and preserve entrepreneurial freedom. This allows corporate cultures to be preserved, and entrepreneurs can focus on their core business and evolving customer needs.
Responsibility for Care
Behind every shipment is a person waiting for their medication. For us, supply security is not just a buzzword, but the standard by which we measure every decision—today and for future generations.
Growth
New customers and Europe-wide bids through the network alliance.
Investment Capacity
Joint investments in the fleet, refrigeration infrastructure, and digitalization.
Quality
Group-wide quality management standards, mutual audits, and shared regulatory expertise.
Participation
The partners play an active role in shaping the Group's standards and strategy.
Market Growth
Demographics, therapeutic innovation, and the reindustrialization of Europe are driving demand in the long term.
Resilience
The supply of medicines is not affected by economic cycles and is critical to the system.
Entrepreneurship
Experienced owners and well-coordinated teams will remain on board, ensuring strong customer relationships, expertise, and operational stability.
Synergies
Network traffic, predictable utilization, joint sales, and a shared, highly efficient quality management system.
Buy & Build
A fragmented market with clear opportunities for consolidation—VITAIRA as a platform.
Barriers to entry
GDP-compliant transportation and storage, along with GMP-certified value-added services, protect established partner companies from new competitors.
